Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Respirable Advanced Therapeutics for Cystic Fibrosis & other Lung Diseases (ReSpire)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Ireland
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2018)
Start date: 2019-02-01
End date: 2019-07-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Via the SME Instrument OmniSpirant Ltd will mature its stem cell exosome-packaged gene therapy with lung mucus penetration properties which will be more effective (improved lung function, reversal of lung damage and superior CFTR gene expression and function) and also be applicable to 100% of the CF global population. This approach, using a combined patent pending exosome surface engineering for enhanced mucus penetration and cell transfection with a tailored vibrating mesh nebulisation aerosol delivery method will provide a unique, potentially disruptive, therapeutic modality for CF and many other lung diseases with high unmet medical need. Our competitive advantage and Unique Selling Points lower current effectiveness barriers and make the OmniSpirant exosome technology the only therapeutic delivery method that could provide a truly effective treatment for CF, thus improving both survival rates the quality of life of CF suffers. Importantly, the quality of life for CF patients will increase to point where they are able to work. The OmniSpirant system will, over time, be regarded as an essential weapon in the armoury of health systems in the battle against other serious respiratory conditions affecting major patient populations such as lung cancer and COPD, globally. The overall objective of our feasibility study is to demonstrate the potential value of the combined gene therapy system maturation based on a comprehensive analysis of the business concept in terms of technical, commercial and financial viability. The outcome of the study will be a full Business Plan that will feed into a Phase 2 project.

Keywords: exosomes,cystic fibrosis,advanced therapy medicinal product,copd,lung cancer
From mechanical control to shape-shifting in supramolecular biomaterials to guide stem cell fate (SupraCTRL)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Synthetic Chemistry and Materials
Panel description: New materials and new synthetic approaches, structure-properties relations, solid state chemistry, molecular architecture, organic chemistry
Countries involved: Netherlands
Call: ERC Starting Grant (ERC-2019-STG, 2019)
Start date: 2020-09-01
End date: 2025-08-31
Duration (months): 60.0
Total project cost (EUR): 2000000.0
EU funding (EUR): 2000000.0
Participants: 1
Project status: SIGNED

The biochemical and biophysical cues of the stem cell environment that act in a concerted and spatiotemporal manner lead to the formation of the 200 cell types and organs of the human body, but how this precisely occurs remains unclear and it is necessary to guide their production for use in the biomedical area. Standard differentiation protocols in vitro mimic known stages in development by the timed addition of biochemical cues on 2D substrates, however these protocols lack the complexity of the 3D natural extracellular matrix (ECM), with its mechanical character that evolves in time. Supramolecular materials can recapitulate the structural and dynamic character of the ECM being based on non-covalent interactions. Moreover, as I have shown, their mechanical soft character can mimic embryonic microenvironment for induced pluripotent stem cell (iPSC) culture but renders them unable to mimic stiff and tough tissues. Double networks using covalent polymers have demonstrated to achieve such mechanical properties, however these materials lack the cytocompatibility for use in 3D cell culture. In this proposal, I will synthesize hybrid covalent-supramolecular polymer networks that use biocompatible chemical and light-activated ligation approaches to apply them to guide the fate of iPSCs to cardiomyocytes by controlling their mechanical properties in time. I will exploit the unique properties of these double networked materials to interface them with biomechanical devices, and as an actuatable culture platform by 3-D printing a miniature beating heart ventricle. These advanced culture platforms based on hybrid-covalent supramolecular materials that go from soft to stiff and tough in time and space with shifting-shapes, with the potential to decouple the presentation of bioactive cues in an integrated manner, will provide uncharted opportunities to understand the spatiotemporal evolution of active and passive mechanical cues in development from cell to organ.
Eastern Romanian Business Support Network support for innovative SMEs (ERBSN 4 H2020)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: Specific Grant agreement
Countries involved: Romania,Romania,Romania,Romania,Romania,Romania
Call: H2020 2D CONSULTATION EEN (H2020-EEN-SGA2-2017-2018, 2016)
Start date: 2017-01-01
End date: 2018-12-31
Duration (months): 24.0
Total project cost (EUR): 97768.75
EU funding (EUR): 97768.75
Participants: 6
Project status: CLOSED

ERBSN 4 H2020 is a 4-partner partnership covering Romanian Macroregion 2 (RO2) and which objective is to address the topic of H2020 - Work Programme 2017-2018. Out of the 4 partners, three are technically involved in delivering H2020 innovation services for SMEs, while the coordinator is involved to administratively deliver the project. With this view, ERBSN 4 H2020 operates a viable macroregional network of 9 innovation experts, of which 3 Key Account Managers, all staff of the 3 ERBSN-EEN centres, able to deliver the two innovation services proposed by H2020. The Key account management (KAM) services will be delivered for 3 SMEs expected to benefit of SMEs Instrument under H2020, and support them receiving the most appropriate services which will enhance the probability of a successful exploitation of their financed innovation projects, over the first two SMEs Instrument phases, while posting them for further EEN services not covered financially by H2020, for phase 3. The services to enhance the innovation management capacities of SMEs with significant innovation activities and potential for international growth will be delivered for 47 SMEs, identified under a thorough analysis of the RO2 innovative businesses, and among the SoE RO2 SMEs under the SMEs Instrument. In order to achieve the specific objectives, ERBSN shall build sinergies with the consortium's services under COSME, in order to stimulate innovation and facilitate SMEs access to H2020 innovation services and funding. Special actions have been proposed under 2017-2018 COSME activities.

Keywords: h2020,sme instrument,innovation services,highly innovative smes,key account managers,enhance the innovation management capacities of smes,phase i,phase ii,imp3rove
High-Throughput Cryogenic Spectroscopy for Glycan Analysis (GLYCANAL)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Physical and analytical chemical sciences
Panel description: Analytical chemistry, chemical theory, physical chemistry/chemical physics
Countries involved: Switzerland
Call: ERC Advanced Grant (ERC-2017-ADG, 2017)
Start date: 2018-09-01
End date: 2023-08-31
Duration (months): 60.0
Total project cost (EUR): 2499801.0
EU funding (EUR): 2499801.0
Participants: 1
Project status: SIGNED

Glycans, or oligosaccharides, are ubiquitous in biological systems. Because they decorate the surface of cells, they play a key role in virtually all cellular recognition processes and are implicated in almost every major disease. Despite their importance, the characterization of glycan primary structure lags far behind that of proteins and DNA because of their intrinsic isomeric complexity. The isomeric nature of the monosaccharide building blocks, the stereochemistry of the glycosidic bond, the possibility of multiple attachment points, and the occurrence of isomeric branched structures all make glycans difficult to analyze. Although mass spectrometry (MS) is one of the most sensitive approaches for glycan analysis, it has difficulty to distinguish all these various types of isomerisms. Ion mobility spectrometry (IMS) combined with MS has demonstrated some ability to identify glycan anomers and regioisomers, but cannot easily distinguish isomeric disaccharides, for example. We have recently demonstrated that cryogenic infrared spectroscopy provides unique vibrational fingerprints of glycans that distinguishes all the various types of isomerism. When combined with simultaneous measurements of mass and ion mobility, these fingerprints can be tabulated in a database and used to identify a given glycan from a mixture. However, adding a spectroscopic dimension to ion mobility and mass measurements requires additional time, which hampers it use as an analytical tool. To use spectroscopic data for real-world glycan analysis, one must multiplex the measurement process and record the vibrational spectrum of many species simultaneously. This project involves designing and constructing an instrument that combines state-of-the-art ion mobility separation, cryogenic ion spectroscopy, and time-of-flight mass spectrometry to perform high throughput analysis of glycan primary structure. The success of this project would represent a tremendous breakthrough for glycoscience.

Keywords: chemical instrumentation,glycomics,glycoscience
Accelerated Early staGe drug diScovery (AEGIS)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Innovative Training Networks (ITN)-European Training Networks
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Germany,Germany,Italy,Spain,Ukraine,Italy,Germany,Switzerland,Poland,Poland,Sweden,Switzerland,Sweden,France,France,Netherlands,Netherlands,United States
Call: Marie Skłodowska-Curie Innovative Training Networks (ITN-ETN) (H2020-MSCA-ITN-2015, 2015)
Start date: 2016-01-01
End date: 2019-12-31
Duration (months): 48.0
Total project cost (EUR): 3836995.92
EU funding (EUR): 3836995.92
Participants: 26
Project status: CLOSED

The development of effective novel drugs - especially for rare and neglected diseases - is one of the biggest challenges of the upcoming decades, as illustrated by the recent Ebola outbreak. Moreover, European innovation in new drug registrations is dramatically falling behind compared to the US and Asia. The principal aim of the AEGIS ITN is to implement the first comprehensive, intersectoral cross-disciplinary and structured curriculum for doctoral students in the European Research Area by establishing a unique training platform for the next generation of European researchers in early drug discovery. A significant added value is provided through networking with key European pharmaceutical companies. A key research aim of AEGIS is improving the efficiency and success of early stage drug development by combining innovative methods and techniques to tackle difficult but promising targets (i.e. protein-protein interactions), as potentially valuable drug targets are often neglected due to the high risk associated with their validation. The consortium joins leading academic and industry researchers in an open innovation environment for innovative drug development in Europe. It is supported by several additional partners and stakeholders in the field. Integrated training of the fellows takes place at the host institute and by secondments, research schools and individual training within the AEGIS network. The scientific training includes complementary skills, management, intellectual property rights, fund raising, communication and career planning. AEGIS will improve the availability of a highly skilled workforce for European industries and research, greatly enhance the employability and the career perspectives of young researchers for academia as well as for industry, and will be the seed of a sustainable development in innovative drug discovery, in particular for rare and neglected diseases.

Keywords: early stage drug discovery,fragment based drug discovery,drug development,rare,neglected diseases,nmr spectroscopy,x ray crystallography,protein protein interactions,allosteric drugs
In Silico testing and validation of Cardiovascular Implantable devices (SIMCOR)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Methods and data
Action type: Research and Innovation actions
Countries involved: Austria,Austria,Germany,Germany,Italy,Romania,Belgium,France,Netherlands,United Kingdom
Call: Accelerating the uptake of computer simulations for testing medicines and medical devices (H2020-SC1-DTH-2020-1, 2020)
Start date: 2021-01-01
End date: 2024-06-30
Duration (months): 42.0
Total project cost (EUR): 7260356.25
EU funding (EUR): 7260356.25
Participants: 12
Project status: SIGNED

The complexity and speed of technological innovation, with increasingly short product cycles, creates huge demand for standardized best practices to apply in-silico validation methods in a statistically robust, repeatable, and efficient way. SIMCor will address this challenge by providing manufacturers of cardiovascular implantable devices with an open, reusable, cloud-based platform for in-silico testing to accelerate development and regulatory approval of their products. The platform will support device validation along the whole R&D pipeline: from initial modelling and in vitro experiments, to animal studies and device implantation and effect simulation on human cohorts. In particular, SIMCor innovative virtual cohort technology will allow to generate and expose new or existing devices to a range of clinically realistic and diversified anatomies and (patho)physiological conditions, also including extensive paediatric populations, meeting the critical need of testing devices in young patients. A standardized multi-level validation process and sensitivity analysis will guarantee statistical credibility for in-silico tests and the platform as a whole, proving solid experimental ground for regulatory authorities, thus accelerating approval and time to market for new products, reducing the burden of human and animal studies and boosting innovation at large. High-priority safety, efficacy and usability endpoints will be investigated, focusing on device implantation and effect simulations in two representative areas: transcatheter aortic valve implantation (TAVI) and pulmonary artery pressure sensors (PAPS). Based on proof-of-validation results and regulatory approval for these use cases, SIMCor will define standard operational procedures (SOPs) and a generalised technical framework for the in-silico testing, validation and regulatory approval of cardiovascular devices, to be put at the service of researchers, medical device manufacturers and regulatory bodies.

Keywords: in silico testing,cardiovascular implantable device,computer modelling,proof of validation,regulatory approval,standards,virtual cohort,virtual implantation,device effect simulation
eMurmur, a software based, clinically tested medical device for automated heart murmur detection (eMurmur)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: SME instrument
Countries involved: Austria
Call: Clinical research for the validation of biomarkers and/or diagnostic medical devices (H2020-SMEINST-1-2015, 2015)
Start date: 2015-07-01
End date: 2015-10-31
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

The auscultation of the heart using a stethoscope is the standard examination method worldwide to screen for heart defects by identifying murmurs. It requires that examining physicians have acute hearing and extensive experience since there is no currently available technology that can perform this test. An accurate diagnosis remains challenging for various reasons including noise, high heart rates, and distinguishing innocent from pathological murmurs. Since objective screening tools are unavailable, the risk of human error increases and current reliance on subjective screening creates issues of consistency, accuracy and objectivity. For example, up to 70% of asymptomatic children who are referred to specialist evaluation or echocardiography because of a suspected murmur are not suffering from heart disease. The result is a high number of patients undergoing unnecessary heart testing. The unnecessary costs, in addition to patient anxiety and inconvenience, in the US alone amount to over a Billion annually. CSD Labs' medical device eMurmur is a clinically tested screening tool for the objective detection of heart murmurs. eMurmur analyses and classifies heart sounds acquired via electronic stethoscopes. The system is comprised of an app that runs on a mobile device and a server-based heart sound analysis software. The app pairs with a commercially available electronic stethoscope, receives and sends the acquired heart sounds to the server for analysis and displays the results to the health care professional on their mobile device. eMurmur can be utilized by medical professionals performing auscultation in their daily routine right at the patients side. Moreover, eMurmur offers medical professionals the capacity to retrieve a PDF report containing all of the above results and additional patient information optionally provided by the user, enabling full documentation of the auscultation and integration into electronic patient files.

Keywords: heart murmurs,echocardiograms,screening
Previble - The Previsualization Tool (Previble)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Action type: SME instrument
Countries involved: Sweden
Call: Open Disruptive Innovation Scheme (H2020-SMEINST-1-2016-2017, 2017)
Start date: 2017-05-01
End date: 2018-02-28
Duration (months): 10.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Previble is an innovation within previsualization, predominantly for the film and entertainment industry. It is a tool to efficiently create digital previsualization in film, TV, video games and other sectors. The technology builds on mostly existing hardware and software solutions. Previsualization in the film- and video games industry is an arduous and expensive task but often needed to ensure that the outcome on screen accurately represents what the creator has envisioned. This new tool will make this process more efficient, less expensive and more enjoyable than any other existing method. By providing the customers with this intuitive versatile solution we can eliminate the barriers that arise between customers and animators and help filmmakers and other creators get their projects closer to their initial vision, and even experiment beyond. The customers can control their work, and the tool can be adapted for groups and crews so they can all work on the same scene at the same time on real-time. Previble has the potential to revolutionise previsualization in the same way as 3D animation did some 30 years ago or storyboards did in the 1930:s. We estimate that the previsualization market is about € 2.55 billion. With this grant we hope to proceed with out feasibility study; understand how to the innovation may be optimized for various customers, including outside our target groups, properly understand the market characteristics, their risks, benefits, and furthermore identify appropriate business model. This tool will be able to service a growing European film and video game industry and simultaneously be accessible and affordable for a large group of European filmmakers who lacks big resources. We believe also that this innovation may not only disrupt the film and entertainment industry, but possibly other sectors where easy to use simulation technologies are in demand, such as architecture and urban planning.

Keywords: previsualization,previble,goodbye kansas,collaborative tool,preproduction,film,media,videogames,urban planning,storyboards,simulation technology
Programmable NanoRobotics for Controlled Manipulation of Molecular Cargoes (ProgNanoRobot)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: United Kingdom
Call: Individual Fellowships (H2020-MSCA-IF-2018, 2018)
Start date: 2019-04-01
End date: 2021-03-31
Duration (months): 24.0
Total project cost (EUR): 224933.76
EU funding (EUR): 224933.76
Participants: 1
Project status: CLOSED

Molecular machines are among the most complex of all functional molecules and lie at the heart of nearly every biological process. The controlled manipulation of molecular-level structures through programmable small-molecule robotics is a fabulous challenge that could lead us towards the dawn of an era of useful molecular nanotechnology. “ProgNanoRobot” project aims to design, construct and investigate the operation of artificial molecular nanorobots capable of transporting a molecule cargo in a programmable fashion. We will develop key methodologies needed to manipulate molecular fragments using a molecular robotic arm operating through the formation and cleavage of dynamic covalent bonds, building on a rotary switch in which the rotor and stator can be positioned with respect to each other. We will explore different component types to find the best programmable small-molecule robotic systems and develop a toolbox of robotic machine components. We will use them as the basis for molecular machines that can transport molecular cargoes of biological relevance over long distances and to select between different cargoes and move them between multiple sites on molecular platforms in either direction. Moreover, we will employ a chemical fuel that induces pH oscillations in the reaction medium to allow the autonomous operation of these systems, a key development to reach the full potential of molecular machines, which will enable them to work as effective molecular assembly lines. We envisage that the domain of this new generation of molecular robotics will be useful for the development of molecular-sized machines that can manipulate substrates to control sequence-specific oligomer construction and molecular manufacturing.

Keywords: artificial molecular machines